|
Lilly’s Cymbalta Nabs Ped Exclusivity, Purdue Studies OxyContin in Children
Eli Lilly’s antidepressant Cymbalta will remain patent protected until December 2013, now that the company has snagged an additional six months U.S. marketing exclusivity by conducting FDA-requested pediatric trials.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives